Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and postoperative dabrafenib + trametinib for papillary craniopharyngioma
2024-517611-67-00Phase 2Authorised
- Sponsor
- Region Skåne
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in Papillary craniopharyngioma (pCP), sponsored by Region Skåne. Planned start Oct 2024; status: authorised.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
Papillary craniopharyngioma (pCP)
Beyond the preview
Go deeper on 2024-517611-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517611-67-00.